Summary by Futu AI
On May 21, 2024, Avenue Therapeutics, Inc. announced that it had received formal notice from The Nasdaq Stock Market LLC confirming the company's compliance with all necessary criteria for continued listing on The Nasdaq Capital Market. This includes meeting the minimum stockholders' equity requirement. The compliance notice effectively closes a previously disclosed listing issue. However, Avenue Therapeutics will be monitored by a Nasdaq Panel for one year until May 21, 2025. During this period, if the company fails to meet the Equity Rule, it will not be allowed to submit a compliance plan but will instead need to request a hearing before the Nasdaq Hearings Panel to address the deficiency.